DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.
[1]. Srikant Viswanadha, et al. Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia. Patent WO2021079273A1.